27 September 2024
27 September 2024
Tagrisso, which targets exon 19 deletions or exon 21 (L858R) mutations, received the approval following a priority review.
The Angelika Amon research building will house 150 employees across 11 floors researching cancer therapies.
Takeda's research team will leverage Tempus' Lens platform, which provides access to anonymised patient data.
The company has previously reported positive data for its PDE4 inhibitor, orismilast, in psoriasis, hidradenitis suppurativa, and ulcerative colitis.
The funding aims to address the urgent demand for new antibiotics to combat the escalating issue of antimicrobial resistance.
The companies will deliver products for diabetes and weight control in specific nations across the Middle East.
KOLs interviewed by GlobalData and surveyed prescribing physicians agreed that there is a gap in the market for safer non-opioid medications that treat addiction and withdrawal.
Direct-to-patient communication is emerging as a powerful solution to the challenges of non-adherence to medication. By leveraging innovative technology, patients can receive personalised reminders, educational content, and support.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
